New drug targets hard-to-treat pancreatic cancer in patients with BRCA mutations
Disease control
Not yet recruiting
This study tests a drug called lorigerlimab in 40 people with advanced pancreatic cancer that has a specific genetic change (BRCA or related genes). The goal is to see if the drug can shrink tumors. Participants must have tried other treatments first. The study is not yet recruit…
Phase: PHASE2 • Sponsor: Peter Hosein, MD • Aim: Disease control
Last updated May 26, 2026 10:34 UTC